Max Chat
Share chart Abeona Therapeutics Inc.
Extended chart
Simple chart
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.Main settings
IPO date
1980-09-19
ISIN
US00289Y2063
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
8.55
Дивиденд ао
3706.25
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 30.36 | 1 |
| P/BV | 5.23 | 3 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -73.71 | 0 |
| ROE | -216.57 | 0 |
| ROIC | 0 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0.5 | 5 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.3589 | 10 |
| Debt/Ratio | 0.2116 | 10 |
| Debt/Equity | 1.47 | 8 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 16.67 | 3 |
| Yield Ebitda, % | 50.73 | 7 |
| Yield EPS, % | -93.49 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 6.16 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 6.22 $ | 0 $ | 0 $ | -0.96 % | 0 % | 0 % |
| Month | 6.42 $ | 6.16 $ | 6.24 $ | -4.05 % | 0 % | 0 % |
| Three month | 4.6 $ | 4.6 $ | 6.87 $ | 33.91 % | 0 % | 0 % |
| Half a year | 5.7 $ | 4.18 $ | 6.87 $ | 8.07 % | 0 % | 0 % |
| Year | 5.54 $ | 4.18 $ | 6.87 $ | 11.19 % | 0 % | 0 % |
| 3 years | 4.08 $ | 2.25 $ | 8.68 $ | 50.98 % | 0 % | 0 % |
| 5 years | 2.92 $ | 0.1365 $ | 8.68 $ | 110.96 % | 0 % | 0 % |
| 10 years | 0.1365 $ | 0.1365 $ | 21.45 $ | 4512.82 % | 0 % | 0 % |
| Year to date | 5.54 $ | 4.18 $ | 6.87 $ | 11.19 % | 0 % | 0 % |
Main owners
| Institutions | Volume | Share, % |
| Nantahala Capital Management, LLC | 4 500 504 | 16.45 |
| Adage Capital Partners GP L.L.C. | 3 249 994 | 11.88 |
| Millennium Management LLC | 1 418 675 | 5.19 |
| Vanguard Group Inc | 1 101 131 | 4.03 |
| Western Standard, LLC | 808 112 | 2.95 |
| AIGH Capital Management LLC | 787 769 | 2.88 |
| Point72 Asset Management, L.P. | 760 870 | 2.78 |
| Ikarian Capital, LLC | 600 000 | 2.19 |
| Citigroup Inc. | 450 347 | 1.65 |
| J. Goldman & Co., L.P. | 429 816 | 1.57 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, CEO & Director | 1.49M | 1976 (49 years) |
| Mr. Brian Kevany Ph.D. | Senior VP, CTO & CSO | N/A | |
| Mr. Gregory Gin | Vice President of Investor Relations & Corporate Communications | N/A | |
| Ms. Alison Hardgrove | Chief People Officer | N/A | |
| Mr. Jon Voss | VP & Head of Quality | N/A | 1960 (65 years) |
| Dr. Madhav Vasanthavada M.B.A., Ph.D. | Senior VP, Chief Commercial Officer & Head of Business Development | N/A | |
| Mr. Carl Denny | Senior Vice President of Regulatory Affairs | N/A | |
| Mr. Joseph Walter Vazzano CPA | Chief Financial Officer | 920.85k | 1984 (41 year) |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Senior VP & General Counsel | 1970 (55 years) |
About company
Address: United States, New York. NY, 1330 Avenue of the Americas - Open in google maps, Open in yandex maps
Website: https://www.abeonatherapeutics.com
Website: https://www.abeonatherapeutics.com
